Empty Lipid Nanoparticles for mRNA Loading
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The delivery of nucleic acids, such as mRNA, to cells is hindered by their instability and low cell permeability, posing a challenge for targeted therapeutic or prophylactic applications.
Innovation Solution
The development of empty lipid nanoparticle compositions comprising ionizable, phospholipid, structural, and PEG-lipids, prepared at low pH and high buffer concentration, which can be loaded with nucleic acids to form filled nanoparticles for enhanced delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nucleic acids are delivered directly to cells, then the therapeutic or prophylactic effect can be achieved, but the instability and low cell permeability of nucleic acids hinder effective delivery
Solution Approach 1:
The patent encapsulates nucleic acids within lipid nanoparticle cores, nesting the unstable nucleic acid payload inside a protective lipid shell. This nesting structure physically protects the nucleic acids from degradation while enabling cellular uptake, directly resolving the contradiction between delivery effectiveness and stability.
Solution Approach 2:
The lipid nanoparticle acts as an intermediary carrier between the nucleic acid payload and the target cells. The ionizable lipids and PEG-lipids in the nanoparticle structure mediate the delivery process, protecting nucleic acids from environmental degradation while facilitating cellular penetration, thus overcoming both stability and permeability issues.
2Manufacturing precision
If lipid nanoparticle compositions are prepared at low pH with high buffer concentration, then uniform particle size and high zeta potential are achieved, but the preparation process complexity increases
Solution Approach 1:
The patent specifies preparing lipid nanoparticle compositions at low pH (pH 3-5) with high buffer concentration (≥30 mM). This parameter change in the preparation conditions controls the ionization state of lipids and buffer capacity, which directly determines particle size uniformity and zeta potential, achieving manufacturing precision through controlled parameter changes.
Solution Approach 2:
The patent performs pH adjustment and buffer addition as preliminary actions before final nanoparticle formation and payload loading. By pre-establishing the optimal low pH and high buffer concentration conditions, the process ensures uniform particle formation and high zeta potential are achieved from the outset, simplifying subsequent steps.
3Productivity
If empty lipid nanoparticle compositions are prepared with high zeta potential, then post-hoc loading efficiency is improved, but the preparation requires specific low pH conditions
Solution Approach 1:
The patent prepares empty lipid nanoparticles at low pH with high buffer concentration as a preliminary step to achieve high zeta potential (≥35 mV) before payload loading. This preliminary action ensures the nanoparticles are optimally prepared for subsequent post-hoc loading, improving loading efficiency while the established protocol makes the process reproducible.
Solution Approach 2:
The patent utilizes the dynamic pH-responsive properties of ionizable lipids, where the low preparation pH creates high zeta potential for efficient loading, and the pH can be subsequently adjusted for stability and delivery. This dynamic behavior enables both high loading efficiency and manageable preparation conditions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach results in stable, uniformly sized nanoparticles with high zeta potential, facilitating effective post-hoc loading and delivery of nucleic acids, thereby overcoming the challenges of instability and permeability.
Implementation Method 1
mixing a lipid solution comprising: (i) an ionizable lipid, (ii) a phospholipid, (iii) a structural lipid, and (iv) a PEG-lipid, with an aqueous buffer solution having a pH of less than about 4.5
Data Source
AI summary
Provided are empty lipid nanoparticle compositions, and processes for their preparation, which are useful in the preparation of therapeutic or prophylactic lipid nanoparticle compositions comprising a therapeutic or prophylactic agent including, for example, nucleic acids such as mRNA.